Category: Healthcare Stocks
-
GLP-1 Drugs: A Promising Study Suggests They Could Help Treat Cancer
GLP-1 therapies are rapidly transforming diabetes and weight-loss treatment, new research suggests they could also weaken cancer growth, and Eli Lilly (NYSE:LLY)’s tirzepatide stands to gain if these findings hold up. In a recent mouse experiment, scientists gave obese animals tirzepatide—Lilly’s blockbuster obesity and diabetes drug—and watched not only a roughly 20% drop in body Read more
-
Can WW International Stock Ride the GLP-1 Hype?
WW International, widely known for its WeightWatchers brand, has been rallying in recent weeks as it looks to benefit from offering GLP-1 weight-loss medications to its customers. But is that enough of a reason to buy this beaten-down stock, which is down around 90% so far this year? High Short Interest Reflects Market Skepticism With Read more
-
DexCom Stock Falls After Underwhelming Q3 Earnings
Dexcom, Inc. (Nasdaq: DXCM) reported disappointing third-quarter 2024 earnings on Thursday, revealing just 2% revenue growth year-over-year to $994.2 million. This slow revenue expansion—particularly driven by a 2% decline in U.S. revenue—comes as the stock continues to trade at an elevated 46 times earnings, raising concerns about its valuation given the lack of strong growth. Read more
-
CVS Health Changes Leadership Amid Financial Struggles
CVS Health replaced its CEO, Karen Lynch, with David Joyner as the company faces financial challenges, especially with its Aetna insurance business. CVS warned that its Q3 earnings will miss expectations, causing shares to drop by more than 7% on Friday morning. The company’s stock has fallen 19% this year, leading to the leadership shift. Read more